FasL (human) (multimeric) (rec.)
Method: Jurkat cells were treated O/N with the indicated concentrations of FasL (human) (multimeric) (rec.) (Prod. No. AG-40B-0130), Fc:FasL, Soluble (human) (rec.) (Prod. No. AG-40B-0132), FasL, Soluble (human) (rec.) (Prod. No. AG-40B-0001) or FasL, Soluble (human) (rec.) + TNF ligands enhancer (Prod. No. AG-44B-0001) (2 fold-dilutions, first concentration of 1000ng/ml). Cell death was quantified using PMS/MTS. The oligomeric FasL recombinant proteins (FasL (human) (multimeric) (rec.), Fc:FasL, Soluble (human) and FasL, Soluble (human) + TNF ligands enhancer) kill Jurkat cells at IC50 <0.2ng/ml.
|Synonyms||MultimericFasL™; MegaFasL; ACRP30headless:APO-1L; ACRP30headless:CD95L; ACRP30headless:CD178; ACRP30headless:TNFSF6; ACRP30headless:Fas Ligand|
|Source/Host||HEK 293 cells|
Human FasL (aa 139-281) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag.
Binds to human and mouse Fas.
Induces apoptosis of human Jurkat T cells at a concentration of <0.2ng/ml.
|Endotoxin Content||<0.02EU/μg purified protein (LAL test).|
|Concentration||0.1mg/ml after reconstitution.|
|Reconstitution||Reconstitute with 100μl sterile water.|
|Formulation||Lyophilized. Contains PBS.|
|Other Product Data||
UniProt link P48023: FasL (human)
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
PBS containing at least 0.1% BSA should be used for further dilutions.
Stable for at least 6 months after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
MultimericFasL™ is a high activity construct in which two trimeric FasL are artificially linked via the collagen domain of ACRP30. This construct very effectively mimics the natural membrane-assisted aggregation of FasL in vivo. FasL is a cytokine that binds to TNFRSF6/Fas, a receptor that transduces the apoptotic signal into cells. It is involved in cytotoxic T cell mediated apoptosis and in T cell development.
FasL treatment of stem cells is a robust method for proliferating cells in culture while improving their stemness properties. Treatment with FasL results in a large quantity of Adipose Derived Stem Cells (ASC) of high quality.
- Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003)
- A Fas agonist induces high levels of apoptosis in haematological malignancies: P. Greaney, et al.; Leuk. Res. 30, 415 (2006)
- Apograft, a Novel Stem Cell Selection Technology, Prevents Graft vs. Host Disease (GvHD) While Preserving Graft vs Leukemia (GvL) Effects: J. Stein, et al.; Biol. Blood Marrow Transplant. 24, 192 (2018)
- ASC- and caspase-8-dependent apoptotic pathway diverges from the NLRC4 inflammasome in macrophages: B.L. Lee, et al.; Sci. Rep. 8, 3788 (2018)
- Fas Promotes T Helper 17 Cell Differentiation and Inhibits T Helper 1 Cell Development by Binding and Sequestering Transcription Factor STAT1: G. Meyer zu Horste, et al.; Immunity 48, 556 (2018)
- Fas-L promotes the stem cell potency of adipose-derived mesenchymal cells: I. Solodeev, et al.; Cell Death Dis. 9, 695 (2018)
- IRF2 transcriptionally induces GSDMD expression for pyroptosis: N. Kayagaki, et al.; Sci. Signal. 12, eaax4917 (2019)
- Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance: H. Levy-Barazany, et al.; Bone Marrow Transplant. 55, 1305 (2020)
- NINJ1 mediates plasma membrane rupture during lytic cell death: N. Kayagaki, et al.; Nature 591, 131 (2021)
- FasL Promotes Proliferation and Delays Differentiation of ASCs: I. Sarel, et al.; Jpn. J. Med. 4, 474 (2021)
- Fas-threshold signalling in MSCs promotes pancreatic cancer progression and metastasis: A. Mohr, et al.; Cancer Lett. 519, 63 (2021)